It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. These results were published in the online April 15 version of The Lancet. […]
Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]
There has been some positive news coming out of the ASCO conference in Florida this past week. One of the most significant pieces of positive news deals with the results of a phase I-II trial of the drug known as MDV3100. Basically, more than half of subjects in the study with castration-resistant prostate cancer responded [...]